Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
出版年份 2022 全文链接
标题
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-08-05
DOI
10.1016/s1470-2045(22)00392-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases
- (2021) Preeti Kanikarla Marie et al. CLINICAL CANCER RESEARCH
- Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas
- (2021) Georgios Kantidakis et al. EUROPEAN JOURNAL OF CANCER
- The foundations of immune checkpoint blockade and the ipilimumab approval decennial
- (2021) Alan J. Korman et al. NATURE REVIEWS DRUG DISCOVERY
- Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
- (2020) Emily Z. Keung et al. CLINICAL CANCER RESEARCH
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
- (2019) Breelyn A Wilky et al. LANCET ONCOLOGY
- Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
- (2019) Amanda R. Dancsok et al. MODERN PATHOLOGY
- Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
- (2018) Sirisha L. Mushti et al. CLINICAL CANCER RESEARCH
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
- (2018) Sandra P D'Angelo et al. LANCET ONCOLOGY
- Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials
- (2018) Run-Cong Nie et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study
- (2018) Martee L. Hensley et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Eribulin in advanced liposarcoma and leiomyosarcoma
- (2017) Elisabetta Setola et al. Expert Review of Anticancer Therapy
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- Efficacy of trabectedin for the treatment of liposarcoma
- (2016) Ritika Zijoo et al. EXPERT OPINION ON PHARMACOTHERAPY
- PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
- (2016) Christopher W. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential for immunotherapy in soft tissue sarcoma
- (2015) William W Tseng et al. Human Vaccines & Immunotherapeutics
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now